ORIGINAL RESEARCH
Accepted on 25 Jul 2025
Decoding the Hypoxic Tumor Microenvironment in Colorectal Cancer for Prognostic Modeling and Therapeutic Target Discovery
doi 10.3389/fimmu.2025.1651749
- 184 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Exploring key pathways in the progression of gastrointestinal diseases based on metabolic reprogramming and developing drugs targeting metabolism
Exploring key pathways in the progression of gastrointestinal diseases based on metabolic reprogramming and developing drugs targeting metabolism
1,889
Total downloads
9,820
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
REVIEW
Published on 15 Jul 2025
Clinical application prospects of traditional Chinese medicine as adjuvant therapy for metabolic reprogramming in colorectal cancer
doi 10.3389/fimmu.2025.1630279
- 1,043 views
REVIEW
Published on 11 Jul 2025
Lipid metabolic reprogramming in colorectal cancer: mechanisms and therapeutic strategies
doi 10.3389/fimmu.2025.1603032
- 1,206 views
ORIGINAL RESEARCH
Published on 16 Jun 2025
Sphingosine-1-phosphate stimulates colorectal cancer tumor microenvironment angiogenesis and induces macrophage polarization via macrophage migration inhibitory factor
doi 10.3389/fimmu.2025.1564213
- 1,587 views
REVIEW
Published on 12 Jun 2025
Endostatin-based anti-angiogenic therapy and immune modulation: mechanisms and synergistic potential in cancer treatment
doi 10.3389/fimmu.2025.1623859
- 1,112 views
REVIEW
Published on 06 May 2025
Mechanism of action and therapeutic value of anoctamin-1 in gastrointestinal cancers
doi 10.3389/fimmu.2025.1599100
- 1,082 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: